Stock Analysis

High Insider Ownership Growth Stocks On Euronext Paris In June 2024

ENXTPA:VU
Source: Shutterstock

Amid a backdrop of moderate gains across major European stock indices, with France's CAC 40 Index experiencing slight upward movement, investors are keenly observing market trends as economic signals present a mixed yet cautiously optimistic outlook. In such an environment, growth companies with high insider ownership on Euronext Paris stand out as potentially robust investment opportunities due to the alignment of interests between company insiders and shareholders.

Top 10 Growth Companies With High Insider Ownership In France

NameInsider OwnershipEarnings Growth
VusionGroup (ENXTPA:VU)13.5%25.2%
Groupe OKwind Société anonyme (ENXTPA:ALOKW)24.8%30.6%
WALLIX GROUP (ENXTPA:ALLIX)19.8%101.4%
La Française de l'Energie (ENXTPA:FDE)20.1%37.7%
Adocia (ENXTPA:ADOC)12.1%104.5%
OSE Immunotherapeutics (ENXTPA:OSE)25.6%79.3%
Icape Holding (ENXTPA:ALICA)30.2%26.1%
Arcure (ENXTPA:ALCUR)21.4%41.7%
Munic (ENXTPA:ALMUN)29.4%150%
MedinCell (ENXTPA:MEDCL)16.4%67.9%

Click here to see the full list of 22 stocks from our Fast Growing Euronext Paris Companies With High Insider Ownership screener.

Here's a peek at a few of the choices from the screener.

MedinCell (ENXTPA:MEDCL)

Simply Wall St Growth Rating: ★★★★★☆

Overview: MedinCell S.A. is a French pharmaceutical company specializing in the development of long-acting injectable medications across multiple therapeutic areas, with a market capitalization of approximately €428.93 million.

Operations: The company generates its revenue primarily from the pharmaceuticals segment, totaling €14.13 million.

Insider Ownership: 16.4%

Revenue Growth Forecast: 40.6% p.a.

MedinCell, a French biotech firm, showcases robust growth prospects with its revenue expected to expand at 40.6% annually, significantly outpacing the French market's 5.8%. Despite recent Phase 3 setbacks in its arthritis treatment trial, improvements in secondary outcomes suggest potential for future success. Analysts predict a substantial 30.4% increase in stock price, aligning with MedinCell's transition to profitability within three years. However, shareholder dilution over the past year and high share price volatility present notable risks.

ENXTPA:MEDCL Ownership Breakdown as at Jun 2024
ENXTPA:MEDCL Ownership Breakdown as at Jun 2024

OVH Groupe (ENXTPA:OVH)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: OVH Groupe S.A. is a global provider of public and private cloud services, shared hosting, and dedicated server solutions, with a market capitalization of approximately €0.98 billion.

Operations: OVH Groupe's revenue is segmented into Public Cloud (€140.71 million), Private Cloud (€514.59 million), and Web Cloud (€179.45 million).

Insider Ownership: 10.5%

Revenue Growth Forecast: 11.1% p.a.

OVH Groupe, a French cloud services provider, is poised for growth with expected revenue increases outpacing the French market's average. Despite a volatile share price and low forecasted return on equity, the company's transition to profitability within three years and significant earnings growth projections highlight its potential. Recent strategic executive hires and expansion into new markets, including a substantial investment in Canadian operations, underscore OVH's commitment to innovation and international market penetration.

ENXTPA:OVH Earnings and Revenue Growth as at Jun 2024
ENXTPA:OVH Earnings and Revenue Growth as at Jun 2024

VusionGroup (ENXTPA:VU)

Simply Wall St Growth Rating: ★★★★★★

Overview: VusionGroup S.A. offers digitalization solutions for commerce across Europe, Asia, and North America, with a market capitalization of approximately €2.18 billion.

Operations: VusionGroup S.A. generates €801.96 million from the installation and maintenance of electronic shelf labels.

Insider Ownership: 13.5%

Revenue Growth Forecast: 21.9% p.a.

VusionGroup S.A. has demonstrated robust growth, with a significant increase in both sales and net income as reported in their latest earnings. The company's future looks promising with expected annual profit growth outpacing the French market significantly over the next three years. Despite this, VusionGroup contends with a highly volatile share price. Analysts project a substantial rise in stock price, aligning with the company's aggressive revenue and earnings forecasts.

ENXTPA:VU Earnings and Revenue Growth as at Jun 2024
ENXTPA:VU Earnings and Revenue Growth as at Jun 2024

Key Takeaways

Ready For A Different Approach?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Valuation is complex, but we're helping make it simple.

Find out whether VusionGroup is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com